Capoccia Edward, Levine Laurence A
Rush University Medical Center, Chicago, USA.
Curr Urol Rep. 2018 May 17;19(7):51. doi: 10.1007/s11934-018-0800-5.
To analyze the literature on the current treatment options for Peyronie's disease (PD).
Intracavernosal injection therapy using collagenase clostridium histolyticum (CCH) has been widely adopted since its FDA approval in 2013. Based on the current evidence, it appears to be moderately efficacious for men with mild curvatures. Although a recent study has shown similar outcomes using a modified protocol requiring fewer injections, CCH remains an expensive medication. Surgery provides the most definitive treatment. The most common adverse effect following surgery is perceived loss of length. Length restoration procedures have recently been developed to address this with promising results reported in small series. There are a variety of medical treatment options for PD, with CCH getting the most attention for being the first drug to be FDA approved for PD treatment. It is the authors' opinion that the non-surgical therapy most likely to provide meaningful results is combination therapy utilizing oral, intralesional, and external traction therapy. Surgery remains the gold standard for definitive treatment.
分析有关佩罗尼氏病（PD）当前治疗选择的文献。
自2013年获得美国食品药品监督管理局（FDA）批准以来，使用溶组织梭菌胶原酶（CCH）的海绵体内注射疗法已被广泛采用。根据目前的证据，对于轻度弯曲的男性，它似乎具有中等疗效。尽管最近一项研究表明，使用要求注射次数更少的改良方案可取得相似的结果，但CCH仍然是一种昂贵的药物。手术提供了最确切的治疗方法。手术后最常见的不良反应是感觉阴茎长度缩短。最近已开发出长度恢复手术来解决这一问题，小规模系列报道显示结果令人鼓舞。PD有多种药物治疗选择，CCH作为首个获得FDA批准用于PD治疗的药物受到了最多关注。作者认为，最有可能产生有意义结果的非手术疗法是采用口服、病灶内注射和外部牵引疗法的联合治疗。手术仍然是确定性治疗的金标准。
